Available Trials

---

• Bladder
• Breast
• Cholangiocarcinoma
• Colorectal
• Endometrial
• Gynecological/Ovarian
• Hematology
• Leukemia
• Lung - Non-Small Cell Lung
• Lymphoma
• Multiple Myeloma
• Myelomas
• Pancreas
• PNH
• Prostate
• Solid Tumor

---

Bladder

• USOR 19094 STAR Ph3 Infigratinib UC w/FGFR3 Alt PROOF302 QBGJ398-302

  USOR 19094: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations. (PROOF302)
  

  Available at Arlington Heights

---

Breast

• USOR 20258 PH2 GDC-9545 ER+/HER2- MBC WO42312

  NOW OPEN: USOR 20258 A Phase II, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Compared with Physician's Choice of Endocrine Monotherapy in Patients With Previously Treated Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (WO42312)
  

  Available at Arlington Heights, Niles

• USOR 19054 SGNTUC-016 HER2CLIMB-02 Ph 3 Tuca/Placebo + T-DM1 HER2+

  HER2+ Breast Trial USOR 19054: A Randomized, Double-Blind, Phase 3 Study of Tucatinib or Placebo in Combination with Ado-Trastuzumab Emtansine (T-DM1) for Subjects with Unresectable, Locally-Advanced, or Metastatic HER2+ Breast Cancer. (HER2CLIMB-02)(SGNTUC-016)
  

  Available at Arlington Heights, Niles

---

Cholangiocarcinoma

• USOR 18264 QBGJ398-301 PROOF Trial STAR Infigratinib vs Gem/Cis Cholangio

  USOR 18264: A Phase 3, Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations. The PROOF Trial (QBGJ398-301)
  

  Available at Arlington Heights, Niles

---

Colorectal

• USOR 19245 2019-013-GLOB1 Ph3 Fruq + Placebo CC (FRESCO-2)

  NOW OPEN USOR 19245 A Global, Multicenter, Randomized, Placebo-Controlled Phase 3 Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care to Placebo Plus Best Supportive Care in Patients with Refractory Metastatic Colorectal Cancer (FRESCO-2)(2019-013-GLOB1)
  

  Available at Arlington Heights

• USOR 20235 G1T28-207 PH3 Trila FOLFOXIRI Beva CC

  NOW OPEN: USOR 20235 PRESERVE 1: A Phase 3 Randomized, Double-Blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (G1T28-207)
  

  Available at Arlington Heights, Niles

• USOR 20157 Plasma Test ColoRec Cancer FRNM-004 Blood Collection Registry

  USOR 20157 PREEMPT CRC: PREvention Employing a Multiomics Plasma-based Test for ColoRectal Cancer (FRNM-004)
  

  Available at Arlington Heights

• USOR 18261 / BMS CA2098HW Met Colorectal Cancer

  USOR 18261: A Phase 3b Randomized Clinical Trial of Nivolumab Alone, or in Combination with Ipilimumab, or an Investigator's Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer. (CA2098HW)
  

  Available at Arlington Heights, Niles

---

Endometrial

• USOR 19221 GOG3041 ENGOT-EN10 PH3 Plac Carbo Pacil Dura +/- Olap DUO -E

  USOR 19221: A Randomized, Multicentre, Double-Blind, Placebo-Controlled, Phase III Study of First-Line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer. (DUO-E) D9311C00001; GOG-3041; ENGOT-EN10
  

  Available at Arlington Heights, Niles

---

Gynecological/Ovarian

• USOR 19200 MIRASOL PH3 Mirve Sora Fallopian IMGN853-0416

  USOR 19200 A Randomized, Open-Label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression. (IMGN853-0416)(MIRASOL)
  

  Available at Arlington Heights, Niles

---

Hematology

• USOR 18130/INCB 39110-309 Ph3 Itacitinib GVHD (GRAVITAS309)

  USOR 18130 INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309.)
  

  Available at Niles, Arlington Heights

• USOR 08160/M07-001 PNH Registry

  USOR 08160 PNH Registry: Primary Objective of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry will Collect Data to Evaluate Safety Data Specific to the Use of Solaris and to Characterize the Progression of PNH as well as Clinical Outcomes, Mortality and Morbidity in Solaris and Non-Solaris Treated Patients. Secondary Objective is Raising PNH Awareness in the Medical Community and Patient/Potential Patient Population. (M07-001)
  

  Available at Niles, Arlington Heights

---

Leukemia

• USOR 19205 U2-VEN-207 Ph2 Ubiltuximab+ Umbralisib+ Venetoc CLL

  USOR 19205 ULTRA-V: A Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)
  

  Available at Arlington Heights, Niles

---

Lung - Non-Small Cell Lung

• USOR 20137 GO41854 PH3 Atez Tira Dura Sg 3 NSCLC

  NOW OPEN USOR 20137: A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Patients with Locally Advanced, Unresectable, Stage III, Non-Small Cell Lung Cancer, Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation (SKYSCRAPER-03) (GO41854)
  

  Available at Arlington Heights, Niles

• USOR 19018 516-005 Mirati Ph 3 Sit + Nivo vs Docetaxel NSCLC

  USOR 19018: A Randomized, Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE) Mirati 516-005
  

  Available at Arlington Heights, Niles

• USOR 19192 Ph3 Tira atezo NSCL GO41717

  USOR 19192 A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, An Anti-Tigit Antibody, In Combination with Atezolizumab, Compared with Placebo In Combination With Atezolizumab, In Patients With Previously Untreated, Locally Advanced, Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer. (GO41717)
  

  Available at Arlington Heights, Niles

• USOR 19044 / D9103C00001 Pacific-4/RTOG-3515 NSCLC

  USOR 19044: A Phase III, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Unresected Stage I/II, Lymph-Node Negative Non-Small Cell Lung Cancer. (D9103C00001)(PACIFIC-4/RTOG-3515)
  

  Available at Niles

---

Lymphoma

• USOR 19062 EZH-302 Ph 1b/3 Taze w/ R2 R/R Fol Lymph

  USOR 19062 A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma (EZH-302)
  

  Available at Arlington Heights, Niles

• usor 20219 SGN35-032 PH2 Brentux+CHOP in Tx Naive PTCL

  NOW OPEN: USOR 20219 A Dual-Cohort, Open-Label, Phase 2, Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects with Peripheral T-Cell Lymphoma (PTCL) with Less Than 10% CD30 Expression. (SGN35-032)
  

  Available at Niles

• USOR 20144 SGN35-031 PH3 Bren Vedo Lena Ritux r/r DLBC Lymph

  USOR 20144: A Randomized, Double-Blind, Placebo-Controlled, Active-Comparator, Multi-Center, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)(SGN35-031)
  

  Available at Arlington Heights, Niles

• USOR 16065/UTX-TGR-205 Ublituximab + TGR-1202 vs TGR-1202 DLBCL NHL

  USOR 16065 Relapsed/Refractory - A Phase 2b, Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma. (UTX-TGR-205)
  

  Available at Niles, Arlington Heights

• USOR 11282/SGN35-015 STAR Brentix in Older Pts w/HL 1L 1st Line

  USOR 11282 1st Line - A Phase 2, Single-Arm, Open-Label Study of Single-Agent Brentuximab Vedotin for Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above.(SGN35-015)
  

  Available at Niles

---

Multiple Myeloma

• USOR 19247 54767414MMY3021 PH3 Dara/Len vs Len NDMM

  USOR 19247 A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatments in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)
  

  Available at Arlington Heights, Niles

---

Myelomas

• USOR 18230 207503 Ph3 R/R MM (DREAMM 7)

  USOR 18230 DREAMM 7: A Multicenter, Open- Label, Randomized, Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma (207503.)
  

  Available at Arlington Heights, Niles

---

Pancreas

• USOR 17160/PANOVA-3: 1L Gemcit = nab-pac Pancreatic (EF-27)

  NEWLY OPENED USOR 17160 / PANOVA-3: Pivotal, Randomized, Open-Label Study of Tumor Testing Fields (TTFields, 150kHz) concomitant with Gemcitabine and Nab-Paclitaxel for Front-Line Treatment of Locally-Advanced Pancreatic Adenocarcinoma (EF-27)
  

  Available at Niles, Arlington Heights

---

PNH

• USOR 08160/M07-001 PNH Registry

  USOR 08160 PNH Registry: Primary Objective of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry will Collect Data to Evaluate Safety Data Specific to the Use of Solaris and to Characterize the Progression of PNH as well as Clinical Outcomes, Mortality and Morbidity in Solaris and Non-Solaris Treated Patients. Secondary Objective is Raising PNH Awareness in the Medical Community and Patient/Potential Patient Population. (M07-001)
  

  Available at Niles, Arlington Heights

---

Prostate

• USOR 19191 CA209-7DX Ph3 Nivo +/- Doce mPC 7DX

  NOW OPEN USOR 19191 A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo, In Combination With Docetaxel, in Men with Metastatic, Castration-Resistant, Prostate Cancer. (CA209-7DX)
  

  Available at Arlington Heights, Niles

---

Solid Tumor

• USOR 19151 / STAR Ph1/2 MRTX849 Advanced Solid Tumors KRAS G12C 849-001

  USOR 19151 A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Sold Tumors with KRAS G12C Mutation (849-001) STAR
  

  Available at Niles

• USOR 19079 STAR Ph2 Pemigatinib Solids FGFR INCB54828-207 Incyte

  USOR 19079 A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)(INCB54828-207)
  

  Available at Arlington Heights, Niles